Christopher Paul German Sells 344 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Stock

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Get Free Report) CAO Christopher Paul German sold 344 shares of the business's stock in a transaction dated Friday, March 21st. The shares were sold at an average price of $54.23, for a total value of $18,655.12. Following the sale, the chief accounting officer now owns 2,889 shares in the company, valued at approximately $156,670.47. The trade was a 10.64 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Christopher Paul German also recently made the following trade(s):

• On Wednesday, February 19th, Christopher Paul German sold 635 shares of Rhythm Pharmaceuticals stock. The stock was sold at an average price of $57.22, for a total transaction of $36,334.70.

Rhythm Pharmaceuticals Stock Up 2.4 %

Shares of Rhythm Pharmaceuticals stock traded up $1.31 on Friday, reaching $54.80. The company's stock had a trading volume of 416,136 shares, compared to its average volume of 511,279. The company has a market capitalization of $3.46 billion, a P/E ratio of -12.66 and a beta of 2.30. The stock has a 50-day moving average price of $55.25 and a 200-day moving average price of $55.03. Rhythm Pharmaceuticals, Inc. has a 52-week low of $35.17 and a 52-week high of $68.58.

Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.03). The company had revenue of $41.83 million during the quarter, compared to analysts' expectations of $38.48 million. Rhythm Pharmaceuticals had a negative return on equity of 367.36% and a negative net margin of 230.07%. Sell-side analysts forecast that Rhythm Pharmaceuticals, Inc. will post -4.32 earnings per share for the current fiscal year.

Remove Ads

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. Needham & Company LLC increased their price objective on shares of Rhythm Pharmaceuticals from $64.00 to $66.00 and gave the stock a "buy" rating in a research note on Tuesday, March 18th. Jefferies Financial Group began coverage on shares of Rhythm Pharmaceuticals in a report on Thursday, January 2nd. They issued a "buy" rating and a $80.00 price target on the stock. JMP Securities reiterated a "market outperform" rating and set a $75.00 price objective on shares of Rhythm Pharmaceuticals in a research note on Monday, December 23rd. HC Wainwright restated a "buy" rating and issued a $70.00 target price on shares of Rhythm Pharmaceuticals in a research note on Monday. Finally, Stifel Nicolaus initiated coverage on Rhythm Pharmaceuticals in a report on Wednesday, March 5th. They set a "buy" rating and a $78.00 target price on the stock. One investment analyst has rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat, Rhythm Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus price target of $69.46.

Institutional Investors Weigh In On Rhythm Pharmaceuticals

Large investors have recently bought and sold shares of the company. SRS Capital Advisors Inc. boosted its stake in shares of Rhythm Pharmaceuticals by 740.7% in the fourth quarter. SRS Capital Advisors Inc. now owns 454 shares of the company's stock worth $25,000 after acquiring an additional 400 shares during the last quarter. Raleigh Capital Management Inc. acquired a new stake in Rhythm Pharmaceuticals during the 4th quarter worth $28,000. SBI Securities Co. Ltd. purchased a new stake in shares of Rhythm Pharmaceuticals during the fourth quarter worth $37,000. R Squared Ltd acquired a new stake in shares of Rhythm Pharmaceuticals in the fourth quarter valued at about $44,000. Finally, State of Wyoming purchased a new position in shares of Rhythm Pharmaceuticals in the fourth quarter worth about $61,000.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.